Data‐driven decomposition and staging of flortaucipir uptake in Alzheimer's disease
Authors:
- Tom EarnestTETom Earnest
- Abdalla BaniABAbdalla Bani
- Braden YangBYBraden Yang
- John J. LeeJLJohn J. Lee
- Tammie L. S. BenzingerTBTammie L. S. Benzinger
- Brian A. GordonBGBrian A. Gordon
- Aristeidis SotirasASAristeidis Sotiras
- For The Alzheimer'S Disease Neuroimaging InitiativeFIFor The Alzheimer'S Disease Neuroimaging Initiative
Open Access
- 29 April 2024
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (6) , 4002-4019
Abstract
INTRODUCTION: Previous approaches pursuing in vivo staging of tau pathology in Alzheimer's disease (AD) have typically relied on neuropathologically defined criteria. In using predefined systems, these studies may miss spatial deposition patterns which are informative of disease progression.METHODS: We selected discovery (n = 418) and replication (n = 132) cohorts with flortaucipir imaging. Non‐negative matrix factorization (NMF) was applied to learn tau covariance patterns and develop a tau staging system. Flortaucipir components were also validated by comparison with amyloid burden, gray matter loss, and the expression of AD‐related genes.RESULTS: We found eight flortaucipir covariance patterns which were reproducible and overlapped with relevant gene expression maps. Tau stages were associated with AD severity as indexed by dementia status and neuropsychological performance. Comparisons of flortaucipir uptake with amyloid and atrophy also supported our model of tau progression.DISCUSSION: Data‐driven decomposition of flortaucipir uptake provides a novel framework for tau staging which complements existing systems.Highlights: NMF reveals patterns of tau deposition in AD. Data‐driven staging of flortaucipir tracks AD severity. Learned flortaucipir patterns overlap with AD‐related gene expression.Keywords
Funding Information
- National Institutes of Health (S10OD025200, 1S10RR022984‐01A1, 1S10OD018091‐01, NIH P30 AG066444, P50 AG00561, P30 NS09857781, P01 AG026276, P01 AG003991, R01 AG043434, UL1 TR000448, R01 EB009352)
- U.S. Department of War (W81XWH‐12‐2‐0012)
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
This publication has 62 references indexed in Scilit:
- APOE ε4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's diseaseAlzheimer's & Dementia, 2022
- Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer DiseaseJAMA Neurology, 2022
- Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer DiseaseJAMA Neurology, 2021
- Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer DiseaseJAMA Neurology, 2021
- [18F]MK‐6240 depicts early and late Braak stages of neurofibrillary tangles in preclinical and symptomatic subjectsAlzheimer's & Dementia, 2020
- Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-βJAMA Neurology, 2020
- Data‐driven approaches for tau‐PET imaging biomarkers in Alzheimer's diseaseHuman Brain Mapping, 2018
- Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral CortexJAMA Neurology, 2017
- In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrumAnnals of Neurology, 2016
- The Preclinical Alzheimer Cognitive CompositeJAMA Neurology, 2014